

**REMARKS**

**Response to Restriction Requirement**

The Examiner requires restriction to one of the following five Groups:

**Group I:** Claims 1-3, drawn to BACE455 polypeptides and their fragments.

**Group II:** Claims 4-6 and 9-11, drawn to polynucleotides encoding BACE455 polypeptide, host cells and vectors.

**Group III:** Claims 12-14, drawn to a ligand able to bind a BACE455 polypeptide.

**Group IV:** Claim 15, drawn to a BACE455 inhibitor.

**Group V:** Claims 17-18, drawn to a method of treating clinical conditions by administration of BACE455 inhibitor.


Applicant hereby provisionally elects **Group III**, which covers claims 12-14, drawn to, according to the Examiner, a ligand able to bind a BACE455 polypeptide, **without traverse**. Applicant reserves the right to file one or more divisional and/or continuation applications directed to the non-elected subject matter.

**CONCLUSION**

In view of the above remarks, early notification of a favorable consideration is respectfully requested. An indication of allowance of all claims is respectfully requested.

Respectfully submitted,

HUNTON & WILLIAMS LLP

By:   
Robert M. Schulman  
Registration No. 31,196

Alexander H. Spiegler  
Registration No. 56,625

Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W., Suite 1200  
Washington, DC 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)